Inhibikase Therapeutics Files 8-K with Material Agreements
Ticker: IKT · Form: 8-K · Filed: May 20, 2024 · CIK: 1750149
Sentiment: neutral
Topics: material-agreement, equity-sale, financial-statements
TL;DR
Inhibikase filed an 8-K on 5/20/24 detailing material agreements and equity sales.
AI Summary
On May 20, 2024, Inhibikase Therapeutics, Inc. entered into a material definitive agreement, likely related to its business operations. The company also disclosed unregistered sales of equity securities and provided financial statements and exhibits. This filing indicates ongoing corporate activities and potential equity transactions.
Why It Matters
This filing signals significant corporate actions and potential equity transactions by Inhibikase Therapeutics, which could impact its financial structure and future operations.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements and unregistered sales of equity, which can introduce financial and operational risks.
Key Numbers
- 26-3407249 — IRS Employer Identification No. (Company identifier)
Key Players & Entities
- Inhibikase Therapeutics, Inc. (company) — Registrant
- May 20, 2024 (date) — Date of Report
- 3350 Riverwood Parkway SE, Suite 1900 Atlanta, Georgia 30339 (address) — Principal Executive Offices
- 001-39676 (company_id) — SEC File Number
FAQ
What is the nature of the material definitive agreement entered into by Inhibikase Therapeutics?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on May 20, 2024.
What type of equity securities were sold unregistered by Inhibikase Therapeutics?
The filing mentions unregistered sales of equity securities but does not provide details on the specific type or amount of securities sold.
When was the report filed and what is the earliest event reported?
The report was filed on May 20, 2024, and the earliest event reported is also dated May 20, 2024.
What is Inhibikase Therapeutics' principal executive office address?
The principal executive offices are located at 3350 Riverwood Parkway SE, Suite 1900, Atlanta, Georgia 30339.
What is the SIC code for Inhibikase Therapeutics?
The Standard Industrial Classification (SIC) code for Inhibikase Therapeutics is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 2,595 words · 10 min read · ~9 pages · Grade level 13.5 · Accepted 2024-05-20 08:55:02
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value IKT The Nasdaq Stock Mark
- $0.0001 — nded Warrants have an exercise price of $0.0001 per share and are immediately exercisab
- $1.68 — of Common Stock at an exercise price of $1.68 per share. The Private Common Warrants
- $1 — Warrant at a combined purchase price of $1.68, and each Pre-Funded Warrant is bein
- $1.6799 — Warrant at a combined purchase price of $1.6799 (equal to the combined purchase price p
- $2.8 million — ayable by the Company, of approximately $2.8 million. The Company intends to use the proceed
- $80,000 — mited to legal fees, up to a maximum of $80,000. If the Registered Direct Offering is n
- $20,000 — mburse Maxim for expenses not to exceed $20,000 in the aggregate. The Placement Agree
- $1.2 million — gregate gross proceeds of approximately $1.2 million from the exercise of the Existing Warra
Filing Documents
- d768660d8k.htm (8-K) — 49KB
- d768660dex41.htm (EX-4.1) — 74KB
- d768660dex42.htm (EX-4.2) — 87KB
- d768660dex43.htm (EX-4.3) — 89KB
- d768660dex44.htm (EX-4.4) — 88KB
- d768660dex45.htm (EX-4.5) — 88KB
- d768660dex46.htm (EX-4.6) — 8KB
- d768660dex51.htm (EX-5.1) — 12KB
- d768660dex101.htm (EX-10.1) — 207KB
- d768660dex102.htm (EX-10.2) — 39KB
- d768660dex103.htm (EX-10.3) — 43KB
- d768660dex991.htm (EX-99.1) — 13KB
- g768660g0520091203107.jpg (GRAPHIC) — 3KB
- g768660g0520091203364.jpg (GRAPHIC) — 2KB
- g768660snap1.jpg (GRAPHIC) — 6KB
- 0001193125-24-142317.txt ( ) — 1172KB
- ikt-20240520.xsd (EX-101.SCH) — 3KB
- ikt-20240520_lab.xml (EX-101.LAB) — 18KB
- ikt-20240520_pre.xml (EX-101.PRE) — 11KB
- d768660d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Number Description 4.1 Form of Pre-Funded Warrant 4.2 Form of Series A Warrant 4.3 Form of Series B Warrant 4.4 Form of Series C Warrant 4.5 Form of Series D Warrant 4.6 Form of Warrant Amendment 5.1 Opinion of McDermott Will & Emery LLP 10.1 Securities Purchase Agreement, dated as of May 20, 2024 10.2 Placement Agency Agreement, dated as of May 20, 2024 10.3 Inducement Letter, dated as of May 20, 2024 23.1 Consent of McDermott Will & Emery LLP (included in Exhibit 5.1) 99.1 Press Release, dated May 20, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 20, 2024 INHIBIKASE THERAPEUTICS, INC. By: /S/ MILTON H. WERNER Milton H. Werner, Ph.D. President and Chief Executive Officer